AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension

The medicine was well tolerated, with no unexpected safety issue

DPIIT signs MoU with Pfizer to strengthen India’s healthcare innovation ecosystem

Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha

Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market

Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product

CapVest to acquire majority stake in STADA

Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth

Quotient Sciences and CPI join forces to accelerate RNA drug development

The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity

This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity

Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility

Phase 1 has a total reactor capacity of 440 kL with 63 reactors

Cupid’s B2B export order book stands at Rs. 100 Cr+

These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI

Syntegon reports H1 2025 EBITDA higher by 41% to €127 million

Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024